What are the similarities and differences between daprestat and suprestat

Daprodustat (Daprodustat) and suprodustat may be different Chinese translations of the same drug, and the common English name is Daprodustat. This naming difference mainly occurs in the translation standards of drug names in different countries or regions. Therefore, clinically, there is no essential difference between the two in terms of pharmacological effects, indications, administration methods and adverse reactions.

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed to treat chronic kidney disease-related anemia (CKD-anemia). It promotes endogenous expression of erythropoietin (EPO) and iron metabolism-related proteins by simulating hypoxia in the body, thereby increasing erythropoiesis. It represents an innovative treatment strategy compared with traditional injectable recombinant human erythropoietin (rhEPO) drugs, and is particularly suitable for patients who cannot tolerate or have insufficient response to injectable EPO.

Daprostat has been approved for marketing in Japan, the United Kingdom and some EU countries, and was approved by the US FDA in 2023 for the treatment of anemia in CKD without dialysis or dialysis. It is one of the first HIF-PHI drugs to achieve widespread clinical application worldwide. The drug is taken orally once daily and has good patient compliance, especially among dialysis patients, and is expected to replace treatment options that require frequent injections. Research data shows that Daprodustat can significantly increase hemoglobin levels in CKD patients, and its efficacy is not inferior to traditional EPO preparations such as darbepoetin alfa. It also has certain advantages in iron utilization. Adverse reactions include hypertension, venous thrombosis, cardiovascular events, etc., which require close clinical monitoring.

It should be pointed out that since dapostat is a new generation drug, its long-term safety is still under further observation. There is currently insufficient evidence to support its superior cardiovascular outcomes in all populations, so it should still be used with caution in high-risk patients. In addition, special caution should be exercised in patients with cancer or those with a history of active bleeding to avoid adverse effects from potential pro-angiogenic effects. From a pharmacokinetic perspective, Daprodustat has a short half-life, and most patients can achieve stable blood concentrations by taking it once a day. Its metabolism is mainly through the liver CYP2C8 enzyme system. In some people, drug interactions may affect its efficacy or safety.

In actual clinical practice, medical staff and patients are often exposed to itAlthough the two names "daprostat" and "suprestat" are essentially the same drug, some Chinese materials may use different translation methods due to differences in commercial names, registration approvals, or translation habits. This situation is more common in the process of international drug promotion, such as Ibrutinib (Ibrutinib), which is also often called ibrutinib. It is recommended that the doctor confirm the drug instructions and registered trademark before using it.

In summary, daprostat, as aHIF pathway activator, represents an important breakthrough in the treatment of CKD-related anemia. Compared with traditional EPO preparations, its oral administration mode, stable increase in hemoglobin levels, and improved iron metabolism have made it rapidly popularized around the world. In the future, with its launch in China and its inclusion in medical insurance, it is expected to become an important part of the treatment of renal anemia.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat